Herpes and Alzheimer’s Tau; Dementia and Autism; Extended Paxlovid for Long COVID

A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, suggesting that tau phosphorylation may act as an innate immune response in Alzheimer’s disease. (Cell Reports)

Topline results from a HEALEY platform trial showed that fosigotifator, an investigational eIF2B activator developed by the longevity company Calico Life Sciences in collaboration with AbbVie, did not meet its primary endpoint in amyotrophic lateral sclerosis (ALS).

Another HEALEY trial — this one testing the eIF2B agonist DNL343 — also failed to slow disease progression in ALS, Denali Therapeutics said.

Linked Medicaid and Medicare records suggested an elevated prevalence of dementia diagnoses in people with autism spectrum disorder. (JAMA Network Open)

Researchers identified a molecular mechanism that underlies some lissencephaly disorders. (Nature)

Anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention did not raise myocardial infarction or stroke risk compared with onabotulinumtoxinA (Botox), according to Medicare data. (JAMA Neurology)

In naturally sleeping mice, the brain appeared to process new and old memories in separate phases. (Nature)

In humans, functional impairments stemming from sleep deprivation were linked with a behavioral deficit in the ability to downregulate unwanted memories. (PNAS)

Extended courses of nirmatrelvir/ritonavir (Paxlovid) had meaningful benefits for some people with long COVID, a small case series suggested. (Communications Medicine)

Childhood exposure to school segregation was tied to late-life cognition in Black adults. (JAMA Network Open)

Here’s what social media is like for people with Alzheimer’s and dementia. (The Atlantic)

Please enable JavaScript to view the comments powered by Disqus.